2.19 Efficacy Measures in an Open-Label Dose-Optimization Study of an Amphetamine Extended-Release Oral Suspension in Children With ADHD

We will report on the additional efficacy of open-label (OL) amphetamine extended-release oral suspension (AMPH EROS) for the treatment of children with ADHD. AMPH EROS has a 1-hour onset of effect and 13-hour duration of action and was approved by the US FDA for the treatment of ADHD in children ages 6–17 years based on a double-blind, placebo-controlled efficacy and safety study. A significant treatment difference in change from the predose SKAMP (Swanson, Kotkin, Agler, M-Flynn, and Pelham) Rating Scale-combined score was observed at the primary endpoint of 4 hours postdose (p < 0.0001) and at each postdose time point (1, 2, 4, 6, 8, 10, 12, and 13 hours).